NCT Number: NCT00093210
Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B
The primary objective of this clinical research study is to establish the bioequivalence of 2 treatments, rFIX and rFIX-R, when given as a 10-minute intravenous bolus infusion.
Looking for future studies?
Notify MeKey information
Conditions
Age range
12 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Moderate to severe hemophilia B (FIX: C ≤2%)
- Previously treated patients (PTPs) with ≥150 documented exposure days
- Age ≥ 12 years (US sites only)
Exclusion criteria
- Detectable factor IX inhibitor defined as ≥0.6 Bethesda Units for pooled plasma reported by the local laboratory (family history of inhibitors will not exclude the patient)
- Patient history of factor IX inhibitor replacement therapy
- Patient unable to be off factor IX replacement therapy for at least 5 days without bleeding
Treatment and study plan
rFIX-R
DrugSponsors and collaborators
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Registry information
Official study title
A Double-Blind, Randomized, Crossover Evaluation of the Pharmacokinetics of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R); and an Open-Label Safety and Efficacy Evaluation of rFIX-R in Previously Treated Patients With Moderate to Severe (FIX:C≤2%) Hemophilia B
Important dates
- Study completion
- 2005
- First posted
- Oct 7, 2004
- Registry last updated
- Dec 5, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy
NCT06399289
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Beijing, Beijing Municipality, China
View Trial DetailsStudy of AAV5-hFIX in Severe or Moderately Severe Haemophilia B
NCT05360706
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Berlin, Germany
View Trial DetailsDose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B
NCT00979238
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Stanford, California, United States
View Trial DetailsHOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients
NCT03569891
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Phoenix, Arizona, United States
View Trial Details